Industry News

Join WhatsApp Channel 

GPAT caoching
  • Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions
    4 December 2025

    Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

    Rentschler Biopharma, a leading global contract development and manufacturing organization for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.
  • Celltrion announces USFDA approval of 300mg strength of OMLYCLO® (omalizumab-igec)
    4 December 2025
    Celltrion announces USFDA approval of 300mg strength of OMLYCLO® (omalizumab-igec)
    Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg/2mL solution in a single-dose prefilled syringe for subcutaneous injection. In the U.S., OMLYCLO will be marketed and distributed exclusively by Celltrion USA, Inc.
  • Sun Pharma introduces its global innovative drug, Ilumya® in India
    3 December 2025
    Sun Pharma introduces its global innovative drug, Ilumya® in India
    Sun Pharmaceutical Industries Ltd. announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.
  • Sandoz launches denosumab biosimilars in Europe
    1 December 2025
    Sandoz launches denosumab biosimilars in Europe
    Sandoz the global leader in affordable medicines, today announced the European launch of Wyost® (denosumab 120 mg) and Jubbonti® (denosumab 60 mg).
  • Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
    1 December 2025
    Novo Nordisk files for FDA approval of a higher dose of Wegovy® injection 7.2 mg
    Novo Nordisk announced the submission of a sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity.
  • BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification
    22 November 2025
    BE’s New 14-Valent Pneumococcal Vaccine Secures WHO Pre-Qualification

    Biological E. Limited (BE), one of India’s leading vaccine and pharmaceutical manufacturers, has announced a major milestone with the World Health Organisation (WHO) granting Pre-qualification (PQ) status to its 14-valent Pneumococcal Conjugate Vaccine, PNEUBEVAX 14 (BE-PCV-14). This achievement marks the company’s 11th vaccine to enter the WHO PQ portfolio, strengthening its presence among global immunisation suppliers.

  • AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India
    18 November 2025
    AstraZeneca Pharma India Limited and Sun Pharma partner to help patients living with Hyperkalaemia in India
    AstraZeneca Pharma India Limited a leading science-led biopharmaceutical company and Sun Pharmaceutical Industries Limited today announced a second brand partnership for Sodium Zirconium Cyclosilicate in India.
  • Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
    17 November 2025
    Sandoz launches TYRUKO® (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
    Sandoz, the global leader in affordable medicines, today announced that TYRUKO® (natalizumab-sztn) is available to patients in the US. Developed by Polpharma Biologics, TYRUKO® is the first and only US Food and Drug Administration (FDA) approved natalizumab biosimilar for the treatment of relapsing forms of multiple sclerosis (MS).
  • Lupin’s Nagpur Unit-1 Clears U.S. FDA Pre-Approval Inspection with No Observations
    17 November 2025
    Lupin’s Nagpur Unit-1 Clears U.S. FDA Pre-Approval Inspection with No Observations
    Global pharmaceutical company Lupin Limited announced today that the United States Food and Drug Administration (U.S. FDA) has successfully completed a product-specific pre-approval inspection at its Unit-1 oral solid dosage facility in Nagpur.
  • Merck to Acquire Cidara Therapeutics, Inc
    17 November 2025
    Merck to Acquire Cidara Therapeutics, Inc

    Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Cidara Therapeutics, Inc, a biotechnology company developing drug-Fc conjugate (DFC) therapeutics, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Cidara for 221.50 USD per share in cash, for a total transaction value of approximately 9.2 billion USD.

Subscribe to Industry News